BridgeBio Oncology Therapeutics, Inc. Financials
BBOT
All currency values in $ millions unless otherwise noted
| Income Statement | DEC 2025 ~2413.8:1 split | DEC 2024 | DEC 2023 |
|---|---|---|---|
| General & Administrative | $25 | $8 | $0 |
| Research & Development | $121 | $73 | – |
| Total Operating Expenses | $146 | $81 | – |
| Operating Income | -$146 | -$81 | -$0 |
| Non-Operating | |||
| Net Interest Expense | – | $8 | – |
| Other Non-Operating Income (Expense) | $12 | $7 | – |
| Income Tax Expense | $0 | $0 | – |
| Net Income | |||
| Net Income | -$134 | -$74 | -$0 |
| EPS (Basic) | -$4.30 | -$5,756.41 | – |
| EPS (Diluted) | -$4.30 | -$5,756.41 | – |
| Weighted Avg Shares (Basic) | 31.1M | 12,903 | – |
| Weighted Avg Shares (Diluted) | 31.1M | 12,903 | – |
| Shares Outstanding | 31.1M | 12,903 | – |
BridgeBio Oncology Therapeutics (BBOT) financials: revenue, profit and margins
BridgeBio Oncology Therapeutics (BBOT) generated about n/a in revenue and -$172 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is BridgeBio Oncology Therapeutics profitable?+
BridgeBio Oncology Therapeutics reported about -$172 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
SourceFinancial statements computed from the 10-Q filed 5 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 10 Nov 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Pharmaceutical Preparations · Pick stocks to compare with BBOT
Held by ETFs
BBOT is in 7 US ETFs. The largest of them, with BBOT's weight in each:
State Street SPDR S&P Biotech ETFXBI0.02%of the fund
iShares Biotechnology ETFIBB0.01%of the fund
Direxion Daily S&P Biotech Bull 3X SharesLABU0.05%of the fund
- CATema Oncology ETFCANC0.48%of the fund
- BBVirtus Biotech Clinical Trials ETFBBC0.70%of the fund
Harbor Active Small Cap Growth ETFSGRW0.37%of the fund
Spot a number that looks wrong? Check it in BBOT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BBOT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.